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SUMMARY 
  Accessible and real-time genotyping for diagnostic, prognostic, or treatment purposes is 
increasingly impelling in diffuse large B-cell lymphoma (DLBCL). Cell-free DNA (cfDNA) is shed into the 
blood by tumor cells undergoing apoptosis and can be used as source of tumor DNA for the 
identification of DLBCL mutations, clonal evolution, and genetic mechanisms of resistance. In this 
study, we aimed at tracking the basal DLBCL genetic profile and its modification upon treatment using 
plasma cfDNA. Ultra-deep targeted next generation sequencing of pretreatment plasma cfDNA from 
DLBCL patients discovered DLBCL-associated mutations that were represented in >20% of the alleles 
of the tumor biopsy with >90% sensitivity and∼100% specificity. Plasma cfDNA genotyping also 
allowed for the recovery of mutations that were undetectable in the tissue biopsy, conceivably 
because, they were restricted to clones that were anatomically distant from the biopsy site.  
  Longitudinal analysis of plasma samples collected under (R-CHOP) chemotherapy showed a 
rapid clearance of DLBCL mutations from cfDNA among responding patients. Conversely, among 
patients who were resistant to R-CHOP, basal DLBCL mutations did not disappear from cfDNA and, 
moreover, among treatment-resistant patients, new mutations were acquired in cfDNA that marked 
resistant clones selected during the clonal evolution. These results demonstrate that cfDNA 
genotyping of DLBCL is as accurate as genotyping of the diagnostic biopsy to detect clonally 
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represented somatic tumor mutations and is a real-time and noninvasive approach to tracking clonal 
evolution and the emergence of treatment-resistant clones. 
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SOMMARIO 
 Il DNA libero circolante (cell-free DNA, cfDNA) viene rilasciato nel sangue dalle cellule tumorali che 
vanno incontro a meccanismi di apoptosi o necrosi, e può essere utilizzato come fonte di DNA tumorale 
per l'identificazione delle mutazioni nel linfoma diffuso a grandi cellule B (DLBCL), dell'evoluzione 
clonale e dei meccanismi genetici di resistenza. In questo studio, abbiamo mirato a rintracciare il 
profilo genetico alla diagnosi del DLBCL e la sua modifica dopo trattamento, utilizzando il cfDNA 
estratto da plasma. Il cfDNA e il DNA genomico ottenuto dalla biopsia tessutale di 50 pazienti affetti 
da DLBCL sono stati sottoposti a ultra-deep next generation sequencing, rilevando mutazioni 
tipicamente associate al DLBCL e rappresentate in> 20% degli alleli della biopsia tumorale, con una 
sensibilità> 90% e una specificità del 100%. La genotipizzazione del cfDNA al plasma ha permesso di 
identificare mutazioni che non erano rilevabili nella biopsia tissutale, presumibilmente perché, a causa 
dell'eterogeneità spaziale del tumore, erano limitate ai cloni che erano anatomicamente distanti dal 
sito della biopsia. L'analisi longitudinale dei campioni di plasma raccolti durante la chemioterapia con 
Rituximab-ciclofosfamide-doxorubicina-vincristina-prednisone (R-CHOP) ha mostrato una rapida 
scomparsa delle mutazioni dal cfDNA tra i pazienti rispondenti al trattamento. Al contrario, nel cfDNA 
dei pazienti resistenti a R-CHOP, non solo le mutazioni identificate alla diagnosi non scomparivano dal 
cfDNA, ma emergevano nuove mutazioni acquisite, indicando la presenza di cloni resistenti selezionati 
durante l'evoluzione clonale.   
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1. INTRODUCTION 
 
 
1.1. Liquid biopsy and cell-free DNA 
 Rarity of neoplastic cells in the biopsy imposes major technical hurdles that prevented large 
genomic studies in aggressive lymphomas, such as diffuse large B-cell lymphoma (DLBCL). Limitations 
in accessing fresh tumor material from DLBCL tissue biopsies has prevented the rapid translation of 
DLBCL gene mutations into prognostic or predictive tools for the clinical practice. Also, serial sampling 
of tumors to track the acquisition of drug-resistance mutations requires a re-biopsy, which may not be 
routinely feasible in the clinical practice. Therefore, alternative accessible sources of tumor DNA may 
help to complement the molecular diagnostic analyses that are routinely carried out on formalin-fixed 
paraffin-embedded (FFPE) tissue biopsies.1 Liquid biopsy-based genotyping from serum/plasma or 
other body fluids coupled with advanced molecular technologies can provide non-invasive method for 
genetic analyses. These samples contain cell-free nucleic acids (cfNAs) which are valuable markers in 
different diagnostic protocols.2 Cell-free fragments of DNA (cfDNA) are shed into the bloodstream by 
tumor cells undergoing apoptosis.3 Accessing tumor cfDNA through the bloodstream has clear 
sampling advantages and allows serial monitoring of disease genetics in real time. cfDNA is also 
representative of the entire tumor heterogeneity, thus enabling to bypass the anatomical biases 
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imposed by tissue biopsies in the reconstruction of the entire cancer clonal architecture, and to identify 
resistant clones that are dormant in non-accessible tumor sites.3  
In DLBCL, cfDNA has been quantified or used to track the tumor clonotypic immunoglobulin gene 
rearrangement for minimal residual disease monitoring.4-7 Conversely, the evidence that cfDNA 
mirrors the underlying tumor genetics in DLBCL and the proof that cfDNA can be used to track in real 
time clonal evolution-driven resistance upon treatment are currently limited to retrospective series.8,9 
 
1.2. Diffuse large B-cell lymphoma (DLBCL) 
 DLBCL is the most common B cell non-Hodgkin lymphoma (B-NHL) in the adult, is an 
aggressive disease that remains incurable in approximately 30% of patients.10 DLBCL arises from the 
clonal expansion of B cells in the germinal center (GC), a specialized microenvironment that forms in 
secondary lymphoid organs upon encounter of a naïve B cell with its cognate antigen, in the context 
of T-cell dependent co-stimulation.10  
Using gene expression profiling (GEP), two molecularly distinct forms of DLBCL were 
identified, resembling either germinal center B-cells (GCB) or activated B-cells (ABC), while additional 
15-30% of cases remain unclassified.11 These two forms were morphologically overlapping but had 
gene expression patterns indicative of different stages of B-cell differentiation.11  
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 Consistent with their putative “cell-of-origin” (COO), GCB DLBCLs display high-level 
expression of the master regulator BCL6 and harbor hypermutated immunoglobulin genes with 
ongoing somatic hypermutation, whereas ABC DLBCLs show activation of NF-B and BCR signaling 
pathways, and upregulation of genes required for plasmacytic differentiation.12 The COO classification 
has been shown to identify distinct DLBCL prognostic subgroups, with GCB DLBCLs being associated 
with a significantly better outcome as compared with the ABC subgroup.13,14 
 
1.3. Genetic lesions common to GCB and ABC DLBCL 
 A large number of genetic lesion are involved in DLBCL pathogenesis, and some are 
commonly shared among GCB and ABC DLBCL. In particular, one commonly disrupted program in 
DLBCL is represented by epigenetic remodeling. The genetic lesions include i) alterations of histone 
modification genes; ii) alterations deregulating BCL6; iii) loss of immune surveillance mechanisms, and 
iv) other lesions. 
 i) Alterations of histone modification genes: up to 30% of cases, with some preference for 
GCB-DLBCL, harbor mutations and/or deletions inactivating CREB- Binding Protein (CREBBP) and, more 
rarely, E1A Binding Protein P300 (EP300), two ubiquitously expressed acetyltransferases that modify 
lysine residues on both histone and non-histone nuclear proteins, modulating the activity of a large 
number of DNA-binding transcription factors.15 CREBBP mutations include truncating events that 
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remove the C-terminal HAT domain and amino acid changes that impair its affinity for Acetyl-CoA, 
severely reducing its enzymatic activity.  
 At least one third of DLBCLs feature mutations in the Lysine Methyltransferase 2D (KMT2D) 
gene. KMT2D encodes for a methyltrasferase that controls epigenetic transcriptional regulation by 
mono-, di- and trimethylating the lysine 4 position of histone 3 (H3K4). While the consequences of 
KMT2D mutations in DLBCL have not been elucidated yet, most events are predicted to generate 
severely truncated proteins lacking the catalytic SET domain, which is required for its 
methyltransferase activity.10  
 ii) Alterations deregulating BCL6: chromosomal rearrangements of the BCL6 (B-cell 
Lymphoma 6 protein) locus characterize as many as 35% of DLBCL patients, although with two- to 
three-fold higher frequencies in ABC-DLBCLs. These balanced, reciprocal recombination events 
juxtapose the coding domain of BCL6 downstream to heterologous promoters derived from alternative 
chromosomal partners, leading to deregulated expression of an intact protein, in part by preventing 
its downregulation during post-GC differentiation.10,16  
 In addition to genetic lesions directly affecting the BCL6 gene, DLBCL have devised a number 
of ways to deregulate the BCL6 function indirectly. Indeed, about 10-15% of DLBCL patients harbor 
gain-of-function somatic mutations in the Myocyte Enhancer Binding Factor 2B (MEF2B) transcription 
factor, a protein highly expressed in the GC and involved in BCL6 transcriptional activation.17,18 
10 
 
Moreover, in 5% of DLBCL cases, loss-of-function mutations/deletions of F-Box Protein 11 (FBXO11) 
impair proteasomal-mediated degradation of the BCL6 protein, which is controlled by this E3 ubiquitin 
ligase.19 
 iii) Loss of immune surveillance mechanisms: in 29% of cases, the beta-2-microglobulin (B2M) 
gene is lost because of structurally disruptive mutations and/or deletions, and another 30% of cases 
lack B2M expression in the absence of genetic lesions, suggesting the existence of additional genetic 
or epigenetic mechanisms of inactivation.20 B2M encodes for an invariant subunit of the HLA class I 
(HLA-I) complex, which is expressed on the surface of all nucleated cells and is required for recognition 
by cytotoxic T lymphocytes. As a result, over 60% of DLBCL lack surface HLA-I expression, which in turn 
may favor lymphomagenesis by allowing evasion from immune surveillance.21 
  iv) Other lesions: Mutations and deletions of TP53 (Tumor Protein 53) remain an important 
pathogenic lesion in ~20% of all DLBCL.22,23 In particular, TP53 mutations affecting its DNA binding 
domain are most important from a prognostic standpoint.24 Also shared across both DLBCL subtypes 
are mutations of the Forkhead box protein O1 (FOXO1) transcription factor. These events cluster 
around a phosphorylation site required for AKT-mediated nuclear-cytoplasmic translocation and 
inactivation of FOXO1, and were suggested to enhance its activity by preventing its nuclear export 
following PI3K signaling.25 
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1.4. Genetic lesions in GCB DLBCL 
 Few lesions had been found preferentially associated with GCB-DLBCL, including i) 
chromosomal translocations of BCL2 and MYC; ii) PTEN alterations; iii) mutations of EZH2 and, iv) 
mutations in the Gα13 pathway. 
 i)  Chromosomal translocations of BCL2 and MYC: BCL2 (B-cell lymphoma 2) is deregulated in 
diffuse large B-cell lymphoma. The t(14;18) translocation causes constitutive overexpression of BCL2 
by juxtaposing it to immunoglobulin heavy chain gene enhancer elements. This translocation is found 
in about 35-45% of GCB cases.26 MYC rearrangements have been detected in approximately 5% to 14% 
of DLBCL and these alterations are frequently associated with BCL2 or BCL6 rearrangements.10,27 Both 
BCL2 and MYC translocations lead to ectopic expression of the involved protein, in part by allowing 
escape from BCL6-mediated transcriptional repression.10 
 ii)  PTEN alterations: Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene 
that can resist the function of PI3K and negatively regulate AKT activity.28 PTEN deletions (mostly 
heterozygous) are detected in 11.3% of DLBCL, and showed opposite prognostic effects in patients 
with AKT hyperactivation and in MYC rearranged DLBCL patients.29 PTEN mutations, detected in 10.6% 
of patients, are associated with upregulation of genes involved in central nervous system function, 
metabolism, and AKT/mTOR signaling regulation. Multi-levels of PTEN abnormalities and dysregulation 
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play important roles in PTEN expression and loss, and that loss of PTEN tumor-suppressor function 
contributes to the poor survival of DLBCL patients with AKT hyperactivation.29 
 iii)  Mutations of EZH2: Histone methyltransferase enhancer of Zeste homolog 2 (EZH2) 
encodes a subunit of polycomb-repressive complex 2 (PRC2) and is responsible for the trimethylation 
of lysine 27 of histone H3 (H3K27me3).30 The EZH2 gene is mutated in about 23% of GCB-DLBCLs. The 
most frequent mutation is a missense affecting the amino acid tyrosine at position 641 (p.Y641), which 
encodes the catalytic site of the SET domain, resulting in a mutant protein that acts synergistically with 
the wild-type enzyme to increase histone H3 trimethylation.31,32 Increased EZH2 expression of tumor 
cells is associated with better prognosis in GCB DLBCL.33 
 iv)  Mutations in the Gα13 pathway: Deep sequencing studies of GCB-DLBCL have revealed 
mutations in G Protein Subunit Alpha 13 (GNA13),34 that encodes for Gα13. Approximately 20% of GCB-
DLBCLs are characterized by structurally damaging mutations in various components of a G-protein 
coupled inhibitory circuit that regulates the growth and local confinement of GCB cells.10 Mutations in 
the Gα13 signaling pathway in DLBCL result in loss of function, and that restoration and/or activation 
of this signaling pathway help reduce tumor growth and progression.35 
 
1.5. Genetic lesions in ABC DLBCL 
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 The genomic landscape of ABC-DLBCL is associated with genetic lesions leading to 
constitutive activation of the NF-B transcription factor,36 and it involves i) Mutations activating the 
BCR signaling pathway; ii) Mutations activating the Toll-Like Receptor (TLR) pathway and, iii) Mutations 
inactivating negative regulators of NF-B. 
 i) Mutations activating the BCR signaling pathway: ABC-DLBCL cells were found to display a 
chronic, active form of BCR (B-cell receptor) signaling.37 Over 20% of patients harbor somatic mutations 
in the Ig superfamily members CD79B (Cluster of Differentiation 79 B) and, at lower frequencies, 
CD79A.10,37,38 In most cases, the mutations replace the first tyrosine residue (p.Y196) in the cytoplasmic 
immunoreceptor tyrosine-based activation motifs (ITAMs).  
 These events are thought to circumvent negative feedback circuits that attenuate BCR 
signaling, thus maintaining it chronically active. In ~9% of ABC-DLBCL, activation of BCR and NF-B is 
sustained by oncogenic mutations of the Caspase Recruitment Domain Family Member 11 (CARD11) 
gene. CARD11 is a major component of the “signalosome” complex, the coordinated recruitment of 
which is required for proper transduction of BCR signaling.39 These events cluster in the exons encoding 
for the protein coiled-coil domain and enhance the ability of CARD11 to transactivate NF-B target 
genes.37,39 
 ii) Mutations activating the Toll-Like Receptor (TLR) pathway: MYD88 (Myeloid differentiation 
primary response 88) mutations are found in one third of ABC-DLBCLs, where they target an invariant 
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residue within the TIR (Toll/IL1 receptor) domain, leading to a L265P substitution.38,40 This mutation 
induces IRAK4 (Interleukin-1 receptor-associated kinase 4) kinase activity and phosphorylation through 
the spontaneous assembly of a protein complex containing IRAK1 and IRAK4, which in turn can activate 
NF-B and JAK/STAT3 transcriptional responses.41 
 iii) Mutations inactivating negative regulators of NF-B: Almost one third of ABC-DLBCL 
harbor biallelic TNFAIP3 (TNF Alpha Induced Protein 3) truncating mutations and/or deletions.42 
TNFAIP3 encodes for a dual function ubiquitin-modification enzyme involved in the termination of NF-
B responses triggered by TLR and BCR stimulation. TNFAIP3 mutations are thought to induce 
inappropriately prolonged NF-B responses.42,43 
 
1.6. DLBCL treatment 
 At present, the combination of rituximab, cyclophosphamide, doxorubicin, vincristine and 
prednisone (R-CHOP) is the gold standard treatment for DLBCL.44 Rituximab is an antibody directed 
against the CD20 protein, which is primarily found on the surface of B cells and is present on many 
lymphoma cells,45 while cyclophosphamide, doxorubicin, vincristine and prednisone are chemotherapy 
agents.46 About 50% to 70% of patients may be cured by R-CHOP chemotherapy. Nevertheless, R-CHOP 
is found to be inadequate in 30% to 40% of patients.47 For these patients, different processes may 
account for their lack of response to R-CHOP. Death related to R-CHOP toxicities, although it is a rare 
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event in young patients, may be observed in 5% of patients older than age 70 years. R-CHOP failures 
are principally due to either primary refractoriness or relapse after reaching a complete response 
(CR).48  
 Mutations of clinical importance in DLBCL affect the TP53 gene, whose variants are 
consistently associated with poor prognosis among patients treated with R-CHOP,49 and the CARD11, 
CD79A, CD79B, and MYD88 genes, whose variants predict the benefit or no benefit from ibrutinib, the 
inhibitor of Bruton's tyrosine kinase (BTK), monotherapy.50 
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2. AIM OF THE STUDY 
 
In this study we aim to demonstrate that cfDNA genotyping of DLBCL:  
 
i) Is as accurate as genotyping of the diagnostic biopsy to detect somatic mutations of allelic 
abundance >20%;  
 
ii)  Is a non-invasive tool to track the emergence of treatment-resistant clones; 
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3. METHODS 
3.1. Patients 
  The study had a prospective, observational, non-intervention, uni-centered design and 
consisted in the longitudinal collection of peripheral blood (PB) samples and clinical data from DLBCL 
patients treated with R-CHOP at the University of Eastern Piedmont.  
  Inclusion criteria were: i) male or female adults >18 years; ii) diagnosis of untreated DLBCL 
after pathological revision; iii) treatment with R-CHOP; iv) evidence of a signed informed consent. A 
total of 50 previously untreated DLBCL patients fulfilled the inclusion criteria were recruited in the 
study from November 2013 to August 2015 as training series (n=30) and from September 2016 to 
October 2016 as validation cohort (n=20) (Table 1). All patients received R-CHOP treatment.  
The following biological material was collected: i) cfDNA isolated from plasma at diagnosis 
before treatment start, during R-CHOP courses (on day 1 of each course before treatment infusion), at 
the end of treatment and at progression, and ii) normal germline genomic DNA (gDNA) extracted from 
PB granulocytes after Ficoll separation. 
 For comparative purposes, tumor gDNA from the paired DLBCL diagnostic tissue biopsy was 
available for 36 patients (extracted from fresh specimens in 25 cases and from FFPE specimens in 11 
cases). In the remaining 14 cases, the leftover of the FFPE diagnostic biopsy was not available or gave 
insufficient amount of DNA for CAPP-seq. In all instances, basal plasma samples were collected in close 
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temporal proximity of the tumor tissue biopsy (7-14 days after diagnostic tissue biopsy) and before 
starting treatment.  
Clinical information were prospectively maintained in the University of Eastern Piedmont 
lymphoma database. Disease response was assessed by PET/CT.51 Patients provided informed consent 
in accordance with local IRB requirements and Declaration of Helsinki.  
Paired plasma cfDNA and normal gDNA from granulocytes collected from 6 healthy donors 
were used to set the experimental and biological background of the ultra-deep next generation 
sequencing (NGS) approach. The study was approved by the Ethical Committee of the Ospedale 
Maggiore della Carità di Novara affiliated with the University of Eastern Piedmont (Protocol Code CE 
112/15). 
 
3.2. Genomic DNA (gDNA) extraction 
PB granulocytes were separated by Ficoll gradient density centrifugation as source of normal 
germline gDNA. Tumor gDNA was isolated from the fresh or FFPE diagnostic tissue biopsies containing 
>70% of tumor cells as estimated by morphology and immunohistochemistry.  
Tumor and normal gDNA were extracted by using the “salting out” protocol.52 PB was diluted 
1:2 with physiological solution (NaCl 0.9%) and then centrifuged in a gradient differentiation Sigma 
DiagnosticTM Histopaque®-1077 Cell Separation Medium (Sigma-Aldrich, St. Louis, MO, USA) solution 
19 
 
to obtain mononuclear white blood cells and granulocytes. Cells were lysed with Lysis Buffer (Tris-HCl 
1M, pH 8.2, NaCl 5M, EDTA 0.5M), SDS 20% and digested with pronase E (20 mg/mL).  
Samples were incubated at 37°C overnight in a shaking incubator. Proteins were precipitated 
with 6M NaCl, and subsequently discarded after centrifugation at 3200 rpm for 20 minutes. DNA was 
isolated by precipitation with pure ethanol and washed three times with 75% ethanol. The excess 
ethanol was evaporated, and the DNA was dissolved with TE buffer (Tris-HCl 1M, pH 8.2 and EDTA 
0.5M). 
 
3.3. Plasma cfDNA extraction 
 30 ml of PB samples were collected in EDTA tubes and centrifuged at 820 g for 10 min to 
separate plasma from cells within one hour from collection. Plasma was then further centrifuged at 
13000 g for 10 min to pellet and remove any remaining cells and stored at -80°C until DNA extraction. 
cfDNA was extracted from 1 ml aliquots of plasma immediately after thawing by using the QIAamp 
circulating nucleic acid kit (Qiagen, Hilden, Germany) and quantified using a SYBR green-based real-
time qPCR assay for the β-globin gene (180-bp amplicon) carried out on StepOnePlus Real-Time PCR 
System (Step One software 2.0; Applied Biosystems, Foster City, CA, USA). 
 
3.4. Library design for hybrid selection 
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 A targeted resequencing gene panel including coding exons and splice sites of 59 genes 
(target region: 207299bp) that are recurrently mutated in DLBCL and other mature B-cell tumors has 
been specifically designed for this project. The gene panel allowed a priori the recovery of at least one 
clonal mutation in 92.6% (95% CI: 83.6-97.5%) of DLBCL patients, as documented by in silico validation 
against public genomic datasets of DLBCL.53-56  
 
3.5. CAPP-seq library preparation and ultra-deep next generation sequencing 
  In the training cohort (n=30), the gene panel was analyzed in plasma cfDNA collected at 
diagnosis, during R-CHOP courses, at the end of treatment, and at progression (total cfDNA 
samples=127), and, for comparative purposes to filter out polymorphisms, in germline gDNA from the 
paired granulocytes. The tumor gDNA from the paired tissue biopsy was also investigated to test the 
accuracy of cfDNA genotyping. 
   In the validation cohort (n=20), the gene panel was investigated in plasma cfDNA collected 
at diagnosis, and in normal and tumor gDNA from paired granulocytes and tissue biopsy, respectively. 
Tumor and germline gDNA from tissues (median=318 ng) were sheared through sonication (Covaris 
M220 focused-ultrasonicator, Woburn, MA, USA) before library construction to obtain 200-bp 
fragments. For plasma cfDNA, which is naturally fragmented, 2-717 ng (median=17 ng) of DNA were 
used for library construction without additional fragmentation.  
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  The next generation sequencing (NGS) libraries were constructed using the KAPA Library 
Preparation Kit (Kapa Biosystems, Wilmington, MA, USA), and hybrid selection was performed with 
the custom SeqCap EZ Choice Library (Roche NimbleGen, Madison, WI, USA). Multiplexed libraries (n=6 
per run) were sequenced using 300-bp paired-end runs on a MiSeq sequencer (Illumina, San Diego, 
CA, USA). 
 
3.6. Bioinformatic pipeline for variant calling 
  Non-synonymous somatic mutation calling in plasma cfDNA was performed separately and 
in blind from mutation calling in tumor gDNA. After CAPP-seq, FASTQ sequencing reads were initially 
deduped through FastUniq v1.1. Then, the deduped FASTQ sequencing reads were locally aligned to 
the hg19 version of the human genome assembly using BWA v.0.6.2 and assembled into a mpileup file 
using SAMtools v.1. Single nucleotide variations and indels were called in plasma cfDNA vs germline 
gDNA, and tumor gDNA vs germline gDNA, respectively, with the somatic function of VarScan2.  
  Variants annotated as SNPs according to dbSNP 138 (with the exception of TP53 variants that 
were manually curated and scored as SNPs according to the IARC TP53 database), intronic variants 
mapping >2 bp before the start or after the end of coding exons, and synonymous variants were 
filtered out. Two independent statistical approaches (Fisher's exact test and Z-test) were then used to 
filter out variants below the base-pair resolution background frequencies in cfDNA across the target 
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region. Only variants that had a significant call in both test were retained (Bonferroni adjusted test 
p<6x10-8). 
 
3.7. Sanger sequencing 
 Sanger sequencing was also used to validate the most abundant plasma cfDNA mutations 
detected by CAPP-seq. PCR primers were designed in the Primer 3 program 
(http://frodo.wi.mit.edu/primer3/). Purified amplicons were subjected to Sanger sequencing and 
compared to the corresponding germline sequences using the Mutation Surveyor Version 4.0.8 
software package (SoftGenetics, State College, PA, USA; http://www.softgenetics.com) after 
automated and/or manual curation. cfDNA from plasma were subjected to Sanger sequencing and 
compared to the corresponding germline. Mutations were then confirmed from both strands on 
independent PCR products. 
 
3.8. Statistical analysis 
  Sensitivity and specificity of plasma cfDNA genotyping were calculated in comparison with 
tumor gDNA genotyping as the gold standard. The analysis was performed with SPSS v.22.0   
23 
 
4. RESULTS 
4.1. Characteristics of the study cohorts 
  The study was based on a prospectively collected consecutive series of 30 newly diagnosed 
DLBCL patients (training cohort) whose characteristics were consistent with an unselected cohort of 
DLBCL (Table 1). Upon R-CHOP treatment, 83.3% (95% CI: 65.9-93.1%; n=25/30) of patients achieved 
a PET/CT negative complete remission, while 16.7% (95% CI: 6.8-34.0%; n=5/30) failed to achieve a 
complete remission. Among patients that achieved complete remission (median follow-up 6 months), 
two relapsed. The median number of cfDNA molecules per ml of plasma at disease presentation was 
771.7 (range: 137.2-18742.5). An independent validation series of 20 consecutive DLBCL patients was 
also assessed to confirm the accuracy of plasma cfDNA genotyping (Table 1). 
 
4.2. Plasma cfDNA genotyping discloses somatic mutations in DLBCL-associated genes 
  To provide the proof of principle that plasma could function as a liquid biopsy for tracking 
recurrently mutated genes in DLBCL, plasma cfDNA collected at presentation from the training cohort 
was genotyped by using CAPP-seq, a targeted ultra-deep NGS approach for plasma cfDNA genotyping 
already validated in solid tumors. In our cohort, 80% or more of the target region covered >1000x in 
all DLBCL and 80% or more of the target region covered >2000x in 17/30 DLBCL.57 Paired normal gDNA 
was also analyzed to confirm the somatic origin of mutations. Overall, within the interrogated genes, 
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66.6% (95% CI: 47.1-82.7%; n=20/30) of patients harbored somatic mutations (total number 129; 
range: 2-13 mutations per patient) that were detectable in plasma cfDNA (Table 2).  
  In order to validate the NGS results, cfDNA was extracted from a second aliquot of plasma, 
and then subjected to a second CAPP-seq and ultra-deep-NGS sequencing. Robustness of the plasma 
cfDNA CAPP-seq approach and of the bioinformatics analysis was documented by the high 
concordance (R2 0.916) of variant calling from the independent duplicate experiments (Figure S1), 
which consistently confirmed all the variants initially discovered in plasma cfDNA, including those of 
low allele frequency, thus excluding their origin from a batch-specific experimental noise.  
  Sanger sequencing consistently detected all plasma cfDNA mutations showing a 
representation within the sensitivity range of this approach (allele frequency >10%) (Figure S2), thus 
validating the CAPP-seq results on a different experimental platform. 
  Consistent with the typical spectrum of mutated genes in DLBCL, plasma cfDNA genotyping 
discovered somatic variants of KMT2D in 30.0% (95% CI: 14.7-49.4%; n=9/30) of cases, TP53 in 23.3% 
(95% CI: 9.9-42.2%; n=7/30), CREBBP in 20.0% (95% CI: 7.7-38.5%; n=6/30), PIM1 and TNFAIP3 in 16.6% 
(95% CI: 5.6-34.7%; n=5/30), EZH2, STAT6, and TBL1XR1 in 13.3% (95% CI: 3.7-30.7%; n=4/30), B2M, 
BCL2, CARD11, CCND3 and FBXW7 in 10.0% (95% CI: 2.1-26.5%; n=3/30), CD58, CD79B and MYC in 
6.6% (95% CI: 0.8-22.0%; n=2/30), EP300, GNA13, MEF2B, MYD88 and TNFRSF14 in 3.3% (95% CI: 0-
17.2%; n=1/30) (Figure 1A). Though the sample size was unpowered to show significant enrichments 
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of mutated genes within cell of origin categories of DLBCL, EZH2 and BCL2 mutations were as expected 
more frequent in germinal-center (GC) DLBCL, while TNFAIP3 and PIM1 mutations were more frequent 
in non-GC DLBCL (Figure 1A).10 
  Among recurrently affected genes, the molecular spectrum of mutations identified in plasma 
cfDNA was highly consistent with that of variants that have been detected in tumor gDNA of published 
DLBCL series and reported in the COSMIC database (Figure 1B and 1C). PIM1 and MYC were affected 
by multiple hotspot mutations that were suggestive of AID (Activation-induced cytidine deaminase)-
related events (Figure 1C; Table 2).58 Notably, patient ID23, who had the t(8;14) MYC translocation, 
also harbored multiple MYC mutations in cfDNA, consistent with the known accumulation of mutations 
in the translocated MYC gene due to the IGH enhancer-driven misfire of somatic hypermutation (Table 
2).59  
Analysis of 6 healthy donors by CAPP-seq did not disclose any somatic mutations in plasma 
cfDNA (Figure S3), suggesting that the ultra-deep NGS and variant calling approaches used in this study 
did not pick up biological or analytical background noises in cfDNA.  
 
4.3. Validation of biopsy-free DLBCL genotyping 
  The fresh or FFPE tissue biopsy of 20 DLBCL patients from the training cohort was genotyped 
by CAPP-seq in blind of the mutational profile recovered in the paired plasma cfDNA. To validate our 
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sequencing approach of FFPE samples, gDNA from paired fresh/FFPE samples processed from the same 
DLBCL biopsy (n=4) was subjected to CAPP-seq. Pairwise analysis of data showed high (96%) 
concordance in variant recovery from FFPE vs fresh samples (Figure S4).  
In order to systematically derive the accuracy of cfDNA genotyping, the results of plasma 
cfDNA genotyping and tumor gDNA genotyping (gold standard; mutation spectrum shown in Figure 
2A) were then compared (Figures 3A-C) in 18 DLBCL training cases provided with the paired 
plasma/tissue samples and informative because mutated within the target region. Sequencing 
coverage of the tumor gDNA was comparable to that of plasma cfDNA (Figure S5).  
  Genotyping of plasma cfDNA collected at diagnosis identified a total of 108 somatic 
mutations, while genotyping of the gDNA from the diagnostic tissue biopsy identified 105 somatic 
mutations. Biopsy-confirmed tumor mutations were detectable with 82.8% (n=87/105, 95% CI: 74.4-
88.9%) sensitivity in pretreatment plasma cfDNA samples (Figure 3B). Biopsy-confirmed tumor 
mutations not discovered in the cfDNA (n=18/105) generally had a low representation in the tissue 
diagnostic biopsy (median allele frequency in the tumor biopsy=5.7%) (Figure 4A and 4B). Consistently, 
by ROC analysis, cfDNA genotyping showed the highest sensitivity (97.1%; 95% CI: 89.5-99.8%; 
n=68/70) in discovering mutations that were represented in >20% of the alleles of the tumor biopsy 
(Figure 4B), thus demonstrating that plasma cfDNA can accurately mirror the profiles of the most 
abundant clones found in tumor tissues. Plasma cfDNA was uninformative on tumor biopsy mutational 
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status in 10% (95% CI: 1.5-31.3%; n=2/20) of DLBCL cases (Figure 3C). The representation of the 
variants in plasma correlated with the LDH levels at DLBCL diagnosis, but not with disease stage (Figure 
S6). 
Plasma cfDNA genotyping disclosed additional 21 somatic mutations that were not detectable 
in the tissue biopsy, including 7 variants affecting PIM1, a known target of somatic hypermutation 
(Figure 2A and 3; Table S4).58 Repeated ultra-deep NGS consistently confirmed these variants, thus 
excluding their origin from a batch-specific experimental noise (Figure S2). Because the target region 
that has been sequenced in the compiled 20 DLBCL patients might support a total of 18,011,440 
potential non-synonymous variants if they were randomly distributed, and considering that only 21 
non-synonymous mutations were detected in plasma cfDNA but not in the tumor biopsy, the false 
positive rate of plasma cfDNA genotyping was 1.16x10-6 corresponding to a specificity >99.99% 
compared to tumor gDNA genotyping. 
As previously reported in other cancer types,60 non-synonymous mutations occurring only in 
plasma cfDNA conceivably represented tumor mutations restricted to clones that were anatomically 
distant from the biopsy site, rather than false positive calls. Though the study lacked a systematic 
multiregional sequencing of tumor samples from multiple anatomical sites, in support of the above 
interpretation are the observations that: i) the plasma cfDNA FBXW7 p.S668G mutation of patient ID9, 
though undetectable in the diagnostic tissue biopsy, was identified in tumor cells from the cytospin of 
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the cerebrospinal fluid collected at the time of isolated meningeal relapse (Figures 5 and 7); and ii) all 
mutations lacking in the diagnostic tissue biopsy disappeared from cfDNA upon achieving complete 
remission of DLBCL.  
Plasma cfDNA was genotyped by CAPP-seq in an independent cohort of 20 consecutive DLBCL. 
Overall, within the interrogated genes, 85.0% (95% CI: 63.1-95.6%; n=17/20) of validation patients 
harbored somatic mutations (total number 83; range: 1-12 mutations per patient) that were 
detectable in plasma cfDNA (Figure 1D; Table S4). The molecular spectrum of mutations identified in 
plasma cfDNA of the validation series was highly consistent with that observed in the training series 
and more in general with that of published DLBCL cohorts (Figure 1E and F). CAPP-seq of paired tumor 
and plasma samples from 16 DLBCL of the validation series confirmed the sensitivity of plasma cfDNA 
genotyping in recovering biopsy-confirmed mutations (Figure 3 D-E). Biopsy-confirmed tumor 
mutations were detectable with 82.8% (n=58/70, 95% CI: 72.2-90.0%) sensitivity in pretreatment 
plasma cfDNA samples. Most of the biopsy-confirmed tumor mutations not discovered in the cfDNA 
had a low representation in the tissue diagnostic biopsy <20% (Figure 4C). Consistently, by ROC 
analysis, cfDNA genotyping showed the highest sensitivity (91.3%; 95% CI: 79.1-97.1%; n=42/46) in 
discovering mutations that were represented in >20% of the alleles of the tumor biopsy (Figure 4D).  
4.4. Longitudinal monitoring of DLBCL genotype by using plasma cfDNA  
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A total of 127 plasma cfDNA samples were sequentially evaluated to assess the dynamics of 
mutations in plasma upon treatment with R-CHOP. Longitudinal analysis showed a rapid clearance of 
DLBCL mutations in the cfDNA among responding patients (Figure 6A). Among patients who were 
primary resistant to R-CHOP (ID12, ID13), DLBCL mutations did not disappear from cfDNA (Figure 6B). 
In one of the two patients who responded to R-CHOP but ultimately had an early relapse in the central 
nervous system (ID9), mutations were still detectable in the plasma cfDNA sample collected while the 
patient was in complete remission (1-month prior relapse). In addition, among patients that were 
primary refractory to R-CHOP or relapsed after treatment, new mutations appeared in the cfDNA that 
conceivably marked resistant clones that were selected during the clonal evolution process taking 
place under the selective pressure of treatment (Figure 7).  
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5. DISCUSSION 
 
By applying a training-validation approach, this study shows that plasma cfDNA genotyping: i) 
is as accurate as genotyping of the diagnostic biopsy to detect somatic mutations of allelic abundance 
>20% in DLBCL; ii) allows the identification of mutations that are undetectable in the tissue biopsy 
conceivably because restricted to clones that are anatomically distant from the biopsy site; and iii) is a 
real-time and non-invasive tool to track clonal evolution and emergence of treatment resistant clones.  
The identification of genomic alterations with clinical relevance in hematologic malignancies is 
increasing the need for assays that can routinely identify tumor mutational profile. Among hematologic 
malignancies with a leukemic component, accessibility of tumor cells in the PB has allowed the fast 
incorporation of gene mutations into genetic prognostic and predictive algorithms.61-63 At variance 
with other hematologic malignancies, DLBCL typically lacks a leukemic involvement, and bone marrow 
dissemination is infrequent.64 Limited access to the tumor material has therefore hampered the 
development and validation of molecular prognostic models in DLBCL, whose molecular stratification 
represents an unmet medical need.65 On these bases, among hematologic malignancies, DLBCL is an 
ideal model in which the liquid biopsy may allow a step forward in the translation of disease genetics 
into clinically useful markers, especially in the era of novel agents that are active in molecular subgroup 
of the disease.50 
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Because of its >90% sensitivity and ~100% specificity, plasma cfDNA is an easily accessible 
source of tumor DNA that allows to accurately profile DLBCL patients for cancer gene mutations 
represented in >20% of the tumor alleles, which is the sensitivity threshold of conventional Sanger 
sequencing methods that are broadly used to characterize tumor tissue specimens. On these bases, 
plasma cfDNA is an effective surrogate of direct tumor genotyping by conventional sequencing for the 
detection of clonally abundant mutations.  
Plasma cfDNA genotyping also informs on variants that are subclonally represented in the 
tumor biopsy, though a proportion (50%) of low abundance mutations (i.e. allele frequency <20% in 
the tumor biopsy) has been missed by our ultra-deep NGS approach conceivably because of its 
chemistry-dependent sensitivity limit of (~10-3). Indeed, the allelic fractions of mutations in tumor 
biopsies and plasma samples are generally correlated, indicating that low abundant mutations in the 
tumor are scantly represented in plasma. The increasing evidence that small subclones have a clinical 
impact on treatment resistance and outcome in B-cell tumors prompts the development of sensitive 
approaches for cfDNA that are capable of exactly mirroring both the clonal and subclonal composition 
of the tumor.66 For example, incorporation of molecular barcoding in the library preparation chemistry 
along with the application of in silico bioinformatics algorithms to suppress background NGS artifacts 
allow to increase the sensitivity of CAPP-seq of up to 15 times.67  
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Plasma cfDNA represents a complementary source of tumor DNA for DLBCL genotyping 
compared to the tissue biopsy. On the one hand, the complete molecular heterogeneity of a tumor 
cannot be adequately assessed by single or even multiple tissue biopsies, whereas cfDNA genotyping 
captures genetic information shed from all sites of the disease. Also, plasma is an accessible source of 
tumor DNA when DNA cannot be retrieved from the diagnostic tissue biopsy (i.e. because of the limited 
size or poor conservation of the specimen). On the other hand, plasma cfDNA genotyping misses a 
proportion of small subclonal mutations. Also, plasma cfDNA genotyping cannot accurately 
differentiate of de novo DLBCL vs transformed tumors, precisely define the DLBCL cell of origin, and 
fully detect tumor chromosomal translocations 9 which can instead be all routinely scored by analyzing 
the tissue biopsy. These notions suggest that the liquid biopsy is not a substitute of the tumor biopsy, 
but instead provides complementary information in DLBCL.  
Treatment for DLBCL is currently undergoing a shift from chemotherapy towards regimens 
incorporating targeted agents.44,50 Along with the clinical development of novel targeted agents in 
DLBCL, mutation-driven mechanisms of resistance to these drugs are increasingly emerging.50 On these 
bases, cfDNA genotyping may be used as a strategy of molecular monitoring to inform on the 
acquisition of targeted drug-resistance in DLBCL. cfDNA analysis can be easily repeated at multiple 
timepoints on plasma samples obtained before, during and after treatment to provide a picture of the 
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changes in tumor genetics, including dynamic changes in the mutation profile that occur during 
therapy.59  
Beside clonal evolution, longitudinal cfDNA genotyping can also inform on residual disease in 
cancer.49 Our CAPP-seq approach does not reach the sensitivity of typical minimal residual disease 
assays, and the number of informative cases (i.e. cases that achieved a radiological remission but 
ultimately relapsed) is small in the present study cohort. Despite such limitations, the observation that, 
among early relapsing patients, low level somatic mutations persisted in plasma while the disease was 
apparently in remission support the development of plasma cfDNA mutational profiling as a tool for 
residual disease surveillance in DLBCL. A CAPP-seq incorporating molecular barcoding coupled with 
bioinformatics that allows the simultaneously tracking of multiple somatic mutations in cfDNA have 
been developed to outperform immunoglobulin sequencing and radiographic imaging for the 
detection of minimal residual disease in DLBCL.9  
There are relatively few studies investigating the importance of the liquid biopsy in DLBCL that 
have shown very promising results with different approaches. In two studies the IGHV-D-J gene 
segment of the rearranged immunoglobulin was used as plasma cfDNA biomarker to identify patients 
at high risk of treatment failure, while in two additional studies cfDNA was used to detect somatic 
mutations.5,6,8,9 The retrospective nature of the previous studies that relied on archival material 
conceivably obtained and handled with different protocols might have precluded a tight control of the 
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pre-analytic factors that have a substantial effect on plasma cfDNA analysis, including the amount of 
“contaminating” DNA coming from circulating cells. The prospective design and the standardized 
protocols for sample processing used in our study allowed to stringently control pre-analytic factors 
that might influence the results of plasma cfDNA genotyping. In less controlled situations such as 
multicentered studies, the use of Cell-Free DNA BCT tubes, that avoid storage-related pre-analytic 
biases, can provide a broadly validated way to obtain stable cfDNA samples.68  
An immediate clinical application of cfDNA genotyping in DLBCL patients is the incorporation 
of this assay within clinical trials to support post-hoc patient stratification according to baseline disease 
genetics, to develop treatment-specific prognostic, predictive or actionable genomic biomarkers, and 
to track treatment resistance in a clinically relevant time-frame and quality standard.   
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Table 1: Clinical data of the 50 previously untreated DLBCL patients included in the study. CR, complete remission; DLBCL, diffuse large B-cell 
lymphoma; ECOG, Eastern Cooperative Oncology Group; F, female; M, male; FFPE, formalin-fixed paraffin embedded; NA, not assessable; GC, germinal 
center; IPI, international prognostic index; LDH, lactate dehydrogenase. 
 
ID Cohort Tissue biopsy Sex Age at diagnosis Ann Arbor stage LDH 
ECOG                     
performance status 
Extranodal sites IPI Cell of origin Treatment response Follow-up (months) 
ID1 Training Frozen F 64 IVX high <2 <2 3 GC CR 11 (progression) 
ID2 Training Frozen F 35 II normal <2 <2 0 non- GC CR 21 
ID3 Training Frozen M 72 IVX high <2 <2 3 GC CR 15 
ID4 Training Frozen F 64 I normal <2 <2 1 non- GC CR 23 
ID5 Training Frozen F 83 IIX high <2 <2 2 GC CR 24 
ID6 Training Frozen F 64 IV high <2 <2 3 non- GC CR 2  (death) 
ID7 Training Frozen M 84 IEX normal <2 <2 1 GC CR 17 
ID8 Training Frozen F 80 III normal <2 <2 2 non- GC CR 21 
ID9 Training Frozen F 61 IVX high <2 >1 4 non- GC CR 4 (progression) 
ID10 Training Frozen M 26 IIX high <2 <2 1 non- GC CR 21 
ID11 Training Frozen M 38 IVX normal <2 <2 1 GC CR 25 
ID12 Training Frozen M 75 IIX normal <2 <2 1 non- GC Less than CR 1 (death) 
ID13 Training Frozen F 74 IVX high <2 >1 4 non- GC Less than CR 10 (death) 
ID14 Training Frozen F 77 IV high <2 >1 4 GC Less than CR 5 (savage treatment) 
ID15 Training Frozen F 41 I normal <2 <2 0 non- GC CR 25 
ID16 Training Frozen M 62 IV high <2 >1 4 non- GC CR 6 
ID17 Training Frozen F 76 III normal <2 <2 2 GC CR 6 
ID18 Training NA M 83 IE normal <2 <2 1 non- GC CR 16 
ID19 Training NA F 52 II normal <2 <2 0 GC CR 14 
ID20 Training NA M 55 III high <2 <2 2 GC CR 10 
ID21 Training FFPE F 64 III high <2 <2 3 GC CR 10 
ID22 Training NA M 82 IV normal <2 >1 3 non- GC CR 10 
ID23 Training FFPE F 76 IV high <2 <2 3 non- GC CR 4 
ID24 Training NA F 66 I normal <2 <2 1 non- GC CR 16 
ID25 Training NA M 76 IV normal <2 >1 3 non- GC CR 12 
ID26 Training NA M 79 IV normal <2 <2 2 non- GC CR 13 
ID27 Training NA M 55 III normal <2 >1 2 non- GC Less than CR 8 (savage treatment) 
ID28 Training FFPE F 81 IV high <2 >1 4 non- GC CR 9 
ID29 Training NA M 54 IE high <2 <2 1 non- GC CR 14 
ID30 Training NA M 63 IIX high <2 <2 3 non- GC Less than CR 5 (savage treatment) 
ID31 Validation  Frozen F 59 III high <2 <2 2 non- GC CR 12 
ID32 Validation  Frozen F 68 IE high >2 <2 3 GC CR 12 
ID34 Validation  Frozen F 49 III high <2 <2 2 non- GC CR 1 
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ID35 Validation  Frozen M 39 III normal <2 <2 1 non- GC CR 6 
ID36 Validation  Frozen F 78 II normal <2 <2 1 non- GC CR 11 
ID37 Validation  Frozen M 69 III high <2 <2 3 GC CR 11 
ID38 Validation  Frozen M 36 IX high <2 <2 1 GC Less than CR 7 (death) 
ID39 Validation  FFPE F 36 IVX high <2 >2 3 non- GC PD 9 (death) 
ID41 Validation  FFPE F 85 III high >2 <2 4 GC PD 8 (death) 
ID42 Validation  FFPE F 77 IV high <2 >1 4 non- GC CR 31 
ID43 Validation  FFPE F 80 IV normal <2 >2 3 non- GC CR 5 
ID44 Validation  NA M 73 IV normal <2 <2 2 GC CR 17 
ID46 Validation  NA F 48 IVX high <2 <2 2 non- GC CR 23 
ID47 Validation  Frozen F 78 IVA high <2 >1 4 non- GC NA 1 
ID48 Validation  FFPE F 72 IIX normal <2 <2 1 non- GC CR 22 
ID49 Validation  FFPE M 72 IIX normal <2 <2 1 GC NA 4 
ID50 Validation  NA F 68 IV high <2 >2 4 GC NA 2 
ID51 Validation  FFPE M 78 IV normal <2 <2 2 non- GC CR 26 
ID52 Validation  FFPE F 46 IIX high <2 <2 1 non- GC CR 26 
ID53 Validation  NA F 56 IV normal <2 <2 1 GC Less than CR 5 
 
Table 2: Somatic non-synonymous mutations discovered by cfDNA genotyping and their validation in tumor gDNA. CHROM, chromosome; POS, 
position; REF, reference allele; VAR, variant allele; AA, aminoacidic change; VAF, variant allele frequency; gDNA, genomic DNA; cfDNA, cell-free DNA. 
 
ID Sample Cohort Gene RefSeq CHROM POS REF VAR cDNA AA 
VAF in tumor gDNA 
(mutated reads/total 
reads) 
VAF in cfDNA  
(mutated reads/total 
reads) 
ID1 Training CREBBP NM_004380.2 chr16 3781353 G A c.5012C>T p.A1671V 74.79 (795/1063) 53.93 (618/1146) 
ID1 Training STAT6 NM_003153.4 chr12 57498345 C T c.1114G>A p.E372K 49.01 (373/761) 29.87 (253/847) 
ID1 Training STAT6 NM_003153.4 chr12 57492817 T G c.1936A>C p.I646L - 3.12 (54/1731) 
ID1 Training TP53 NM_000546.5 chr17 7578454 G A c.476C>T p.A159V 60.58 (355/586) 34.69 (273/787) 
ID3 Training BCL2 NM_000633.2 chr18 60985877 C T c.23G>A p.G8E 1.76 (48/2732) - 
ID3 Training CARD11 NM_032415.4 chr7 2976810 T A c.1202A>T p.D401V 43.77 (1935/4421) 8.25 (357/4329) 
ID3 Training EZH2 NM_004456.4 chr7 148506437 G A c.2075C>T p.A692V 13.03 (873/5004) 1.9 (60/3151) 
ID3 Training GNA13 NM_006572.4 chr17 63052437 A T c.275T>A p.V92E 61.02 (620/1016) 14.97 (69/461) 
ID3 Training KMT2D NM_003482.3 chr12 49425896 G A c.12592C>T p.R4198* 39.68 (873/2200) 3.77 (128/3395) 
ID4 Training HIST1H1E NM_005321.2 chr6 26156937 C T c.319C>T p.L107F 17.69 (222/1255) - 
ID4 Training ITPKB NM_002221.3 chr1 226923964 C T c.1196G>A p.S399N 13.86 (154/1111) - 
ID4 Training ITPKB NM_002221.3 chr1 226924421 C G c.739G>C p.E247Q 5.51 (72/1307) - 
ID4 Training ITPKB NM_002221.3 chr1 226924604 G A c.556C>T p.P186S 5.93 (55/928) - 
ID4 Training ITPKB NM_002221.3 chr1 226923733 A GCATTCT c.1420_1426del7bp p.R474fs*13 7.33 (89/1214) - 
ID4 Training PCLO NM_033026.5 chr7 82784833 T +30bp c.1123_1124ins30bp p.Q375Ins10AA 2.73 (34/1244) - 
ID4 Training PCLO NM_033026.5 chr7 82584246 G C c.6023C>G p.T2008R 32.30 (686/2124) - 
ID4 Training TBL1XR1 NM_024665.4 chr3 176756172 T -ACA c.973_975del3bp p.C325DelC 19.59 (269/1104) - 
ID5 Training CCND3 NM_001760.4 chr6 41903745 C +G c.811_812insC p.P271fs* 45.79 (1115/2435) 6.99 (84/1201) 
ID5 Training EP300 NM_001429.3 chr22 41573446 C T c.5731C>T p.P1911S 0.89 (33/3716) - 
ID5 Training FBXW7 NM_033632.3 chr4 153244092 G A c.2065C>T p.R689W 46.40 (1979/4265) 6.11 (205/3357) 
ID6 Training KMT2D NM_003482.3 chr12 49434090 G A c.7463C>T p.S2488L 4.21 (40/951) 3.34 (19/569) 
ID6 Training MYD88 NM_002468.4 chr3 38182292 G A c.728G>A p.S243N 10.49 (284/2708) 28.19 (1074/3810) 
ID6 Training PIM1 NM_001243186.1 chr6 37138769 C G c.475C>G p.H159D - 1.43 (33/2303) 
ID6 Training PIM1 NM_001243186.1 chr6 37139237 C T c.850C>T p.L284F - 4.29 (91/2121) 
ID6 Training TNFAIP3 NM_001270508.1 chr6 138200167 A +C c.1585_1586insC p.T529fs*5 6.08 (200/3291) 12.01 (412/3431) 
ID6 Training TP53 NM_000546.5 chr17 7577094 G A c.844C>T p.R282W 7.97 (207/2597) 15.72 (469/2984) 
ID7 Training B2M NM_004048.2 chr15 45003780 A -CT c.37_38delCT p.L13fs*43 60.92 (410/673) 0.87 (6/692) 
ID7 Training BCL2 NM_000633.2 chr18 60985757 A C c.143T>G p.I48S 34.37 (221/643) 0.62 (9/1451) 
ID7 Training CREBBP NM_004380.2 chr16 3795276 A T c.3914+2T>A   37.69 (798/2117) 1.99 (51/2559) 
ID7 Training EZH2 NM_004456.4 chr7 148508728 A T c.1936T>A p.Y646N 31.12 (539/1732) 0.95 (15/1577) 
ID7 Training KMT2D NM_003482.3 chr12 49445616 A G c.1850T>C p.L617P 4.61 (64/1389) - 
ID7 Training KMT2D NM_003482.3 chr12 49441770 T C c.4214A>G p.H1405R 34.33 (505/1471) 1.7 (38/2230) 
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ID7 Training LRP1B NM_018557.2 chr2 141201923 C T c.10270G>A p.D3424N - 1.32 (23/1739) 
ID7 Training SPEN NM_015001.2 chr1 16256910 C G c.4175C>G p.S1392* 39.81 (1207/3032) 1.2 (46/3829) 
ID7 Training TBL1XR1 NM_024665.4 chr3 176767845 A T c.642T>A p.C214* 38.50 (954/2478) 2.69 (44/1637) 
ID7 Training TNFRSF14 NM_003820.2 chr1 2491336 T G c.379T>G p.C127G 54 (27/50) - 
ID8 Training NOTCH2 NM_024408.2 chr1 120458053 T C c.7292A>G p.H2431R 2.79 (19/681) - 
ID8 Training NOTCH2 NM_024408.2 chr1 120458048 C -AGAGT c.7292_7296del5bp p.H2431fs*3 36.7 (407/1109) 11.47 (233/2031) 
ID8 Training TBL1XR1 NM_024665.4 chr3 176756174 C -AAG c.971_973del3bp p.S324DelS 35.62 (285/800) 5.62 (65/1157) 
ID8 Training TP53 NM_000546.5 chr17 7577559 G A c.722C>T p.S241F 14.72 (29/197) 0.72 (9/1251) 
ID8 Training XPO1 NM_003400.3 chr2 61711077 T C c.2672A>G p.D891G 32.13 (187/582) 6.3 (52/825) 
ID9 Training CCND3 NM_001760.4 chr6 41903692 C G c.865G>C p.A289P 30.40 (642/2112) 6.22 (84/1351) 
ID9 Training FBXW7 NM_033632.3 chr4 153244155 T C c.2002A>G p.S668G - 1.38 (75/5429) 
ID9 Training PCLO NM_033026.5 chr7 82579618 T A c.10286A>T p.N3429I 4.29 (164/3827) 0.47 (26/5511) 
ID9 Training SPEN NM_015001.2 chr1 16261296 C T c.8561C>T p.S2854F 26.49 (648/2446) 1.79 (99/5535) 
ID9 Training SPEN NM_015001.2 chr1 16255679 G T c.2944G>T p.E982* 65.82 (4167/6331) 8.59 (638/7425) 
ID10 Training ATM NM_000051.3 chr11 108236105 A G c.9041A>G p.Q3014R - 0.47 (23/4853) 
ID10 Training BCL2 NM_000633.2 chr18 60985405 C G c.495G>C p.E165D 34.30 (3363/9804) 1.61 (62/3842) 
ID10 Training BCOR NM_017745.5 chrX 39932419 G A c.2180C>T p.P727L - 1.31 (31/2358) 
ID10 Training CHD2 NM_001271.3 chr15 93521519 C T c.2633C>T p.S878L - 0.62 (31/5007) 
ID10 Training CREBBP NM_004380.2 chr16 3786036 C T c.4728+1G>A   28.38 (1242/4376) 1.25 (45/3590) 
ID10 Training EZH2 NM_004456.4 chr7 148508727 T A c.1937A>T p.Y646F 52.94 (3331/6292) 1.67 (50/2999) 
ID10 Training KLHL6 NM_130446.2 chr3 183273174 G A c.268C>T p.L90F 47.86 (3025/6321) 2.4 (69/2881) 
ID10 Training MYC NM_002467.4 chr8 128750803 C G c.340C>G p.L114V 1.42 (94/6620) - 
ID10 Training MYC NM_002467.4 chr8 128750684 C T c.221C>T p.P74L 10.24 (308/3008) - 
ID10 Training MYC NM_002467.4 chr8 128750625 G C c.162G>C p.E54D 34.99 (1978/5653) 0.17 (4/2334) 
ID10 Training MYC NM_002467.4 chr8 128750843 A G c.380A>G p.N127S 35.20 (2777/7890) 1.15 (56/4883) 
ID10 Training PCLO NM_033026.5 chr7 82582514 C G c.7755G>C p.L2585F - 0.66 (27/4111) 
ID10 Training PCLO NM_033026.5 chr7 82579795 C A c.10109G>T p.S3370I - 0.66 (33/4990) 
ID10 Training PCLO NM_033026.5 chr7 82580115 C T c.9789G>A p.M3263I - 0.72 (36/4977) 
ID11 Training TP53 NM_000546.5 chr17 7577594 A -CAGT c.683_686del4 p.D228fs*18 15.81 (163/1031) - 
ID12 Training BRAF NM_004333.4 chr7 140453193 T C c.1742A>G p.N581S 62.65 (3573/5703) 3.99 (87/2181) 
ID12 Training NOTCH1 NM_017617.3 chr9 139391369 G -GA c.6820_6821delTC p.S2274fs*79 4.16 (83/1993) - 
ID12 Training TP53 NM_000546.5 chr17 7579484 T +CTGG c.202_203ins4 p.E68fs*82 81.91 (1200/1465) 0.51 (10/1950) 
ID12 Training ZMYM3 NM_005096.3 chrX 70460810 T A c.4069A>T p.I1357F 86.68 (742/856) 1.35 (17/1255) 
ID13 Training EP300 NM_001429.3 chr22 41560092 A G c.3764A>G p.H1255R - 27.65 (885/3201) 
ID13 Training ID3 NM_002167.4 chr1 23885728 G A c.190C>T p.L64F 40.28 (1705/4233) 19.17 (696/3631) 
ID13 Training KMT2D NM_003482.3 chr12 49422609 A C c.14382+2T>G   17.54 (455/2594) 10.2 (332/3254) 
ID13 Training KMT2D NM_003482.3 chr12 49426961 G A c.11527C>T p.Q3843* 37.13 (874/2354) 19.97 (543/2719) 
ID13 Training PIM1 NM_001243186.1 chr6 37138901 C T c.514C>T p.P172S - 0.83 (28/3378) 
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ID13 Training PIM1 NM_001243186.1 chr6 37138908 G A c.521G>A p.G174D - 1.15 (38/3305) 
ID13 Training TBL1XR1 NM_024665.4 chr3 176756174 C A c.974G>T p.C325F 40.93 (562/1373) 13.59 (238/1751) 
ID13 Training TNFAIP3 NM_001270508.1 chr6 138199594 G T c.1012G>T p.E338* 67.75 (1714/2530) 35.23 (856/2430) 
ID13 Training TP53 NM_000546.5 chr17 7577538 C T c.743G>A p.R248Q 68.37 (1314/1922) 32.01 (894/2793) 
ID15 Training ATM NM_000051.3 chr11 108168100 G T c.4996G>T p.E1666* 16.51 (389/2356) 41.25 (905/2194) 
ID15 Training B2M NM_004048.2 chr15 45007727 C -TT c.175_176delTT p.L59fs*8 22.29 (820/3678) 33.5 (671/2003) 
ID15 Training PCLO NM_033026.5 chr7 82580704 C T c.9200G>A p.R3067K 4.08 (147/3599) 13.49 (400/2966) 
ID15 Training POT1 NM_015450.2 chr7 124467278 A G c.1676T>C p.L559P 17.39 (358/2059) 43.19 (827/1915) 
ID15 Training STAT6 NM_003153.4 chr12 57496255 C T c.1330G>A p.E444K 27.42 (811/2958) 36.75 (781/2125) 
ID15 Training TP53 NM_000546.5 chr17 7579415 C T c.272G>A p.W91* 9.27 (243/2621) 13.91 (324/2330) 
ID16 Training CD58 NM_001779.2 chr1 117086941 T -AAAG c.352_355del4bp p.Y117fs*12 25.51 (504/1976) 33.43 (1365/4083) 
ID16 Training CD58 NM_001779.2 chr1 117064573 T -G c.660delC p.P220fs*4 26.94 (284/1054) 40.48 (1144/2826) 
ID16 Training CD79B NM_001039933.1 chr17 62006798 T G c.590A>C p.Y197S 28.2 (238/844) 36.97 (505/1366) 
ID16 Training CREBBP NM_004380.2 chr16 3817738 G T c.3233C>A p.S1078* 31.03 (650/2095) 37.3 (1593/4271) 
ID16 Training KLHL6 NM_130446.2 chr3 183273248 A G c.194T>C p.L65P 1.39 (201/1446) 13.71 (295/2151) 
ID16 Training KLHL6 NM_130446.2 chr3 183273170 G C c.272C>G p.A91G 9.83 (76/773) 15.77 (194/1230) 
ID16 Training KLHL6 NM_130446.2 chr3 183273223 A C c.219T>G p.D73E 32.08 (502/1565) 32.09 (750/2337) 
ID16 Training KMT2D NM_003482.3 chr12 49443617 G A c.3754C>T p.R1252* 56.68 (721/1272) 80.41 (2812/3497) 
ID16 Training NOTCH2 NM_024408.2 chr1 120458372 G A c.6973C>T p.Q2325* 29.08 (301/1035) 40.27 (1119/2779) 
ID16 Training PIM1 NM_001243186.1 chr6 37139167 G C c.780G>C p.K260N - 1.35 (26/1926) 
ID16 Training PIM1 NM_001243186.1 chr6 37138651 T A c.458T>A p.L153* - 3.36 (35/1041) 
ID16 Training PIM1 NM_001243186.1 chr6 37138808 G A c.513+1G>A   26.74 (368/1376) 33.78 (629/1862) 
ID16 Training PIM1 NM_001243186.1 chr6 37140894 C A c.1003C>A p.H335N 28.79 (463/1608) 39.52 (1180/2986) 
ID17 Training BCL2 NM_000633.2 chr18 60985644 G A c.256C>T p.L86F 26.14 (177/677) 4.44 (16/360) 
ID17 Training CREBBP NM_004380.2 chr16 3788618 G A c.4336C>T p.R1446C 21.8 (801/3674) 5.6 (110/1965) 
ID17 Training EZH2 NM_004456.4 chr7 148508727 T G c.1937A>C p.Y646S 36.43 (1242/3409) 5.97 (139/2328) 
ID17 Training KMT2D NM_003482.3 chr12 49444250 G A c.3121C>T p.Q1041* 20.92 (627/2997) 3.27 (25/765) 
ID17 Training KMT2D NM_003482.3 chr12 49433620 G A c.7933C>T p.R2645* 22.05 (741/3360) 5.68 (97/1709) 
ID17 Training MAP2K1 NM_002755.3 chr15 66774131 G A c.607G>A p.E203K 3.15 (75/2380) - 
ID17 Training MEF2B NM_001145785.1 chr19 19260128 G -AA c.163_164delTT p.F55fs*28 22.36 (588/2630) 8.07 (125/1548) 
ID17 Training STAT6 NM_003153.4 chr12 57498348 A G c.1111T>C p.C371R 20.27 (238/1174) 5.02 (95/1892) 
ID17 Training TNFRSF14 NM_003820.2 chr1 2488123 G A c.20G>A p.W7* 13.26 (127/958) 1.77 (18/1016) 
ID19 Training B2M NM_004048.2 chr15 45003773 T C c.29T>C p.L10P NA 8.43 (43/510) 
ID19 Training CARD11 NM_032415.4 chr7 2979559 C T c.688G>A p.D230N NA 2.88 (55/1907) 
ID19 Training HIST1H1E NM_005321.2 chr6 26157009 C T c.391C>T p.P131S NA 1.71 (29/1696) 
ID19 Training LRP1B NM_018557.2 chr2 141751573 C G c.2635G>C p.V879L NA 1.49 (21/1409) 
ID19 Training LRP1B NM_018557.2 chr2 141232880 T C c.9452A>G p.E3151G NA 4.52 (78/1726) 
ID21 Training CREBBP NM_004380.2 chr16 3788618 G A c.4336C>T p.R1446C 21.71 (345/1589) 5.79 (120/2074) 
54 
 
ID21 Training KMT2D NM_003482.3 chr12 49443844 GCTGT G c.3523_3526del4bp p.T1175fs*36 - 7.55 (126/1669) 
ID21 Training KMT2D NM_003482.3 chr12 49416115 G A c.16360C>T p.R5454* 22.35 (76/340) 9.89 (91/920) 
ID21 Training PCLO NM_033026.5 chr7 82546096 T C c.11206A>G p.T3736A NA 0.85 (21/2474) 
ID22 Training KMT2D NM_003482.3 chr12 49447293 G A c.805C>T p.Q269* NA 1.89 (32/1697) 
ID22 Training TNFAIP3 NM_001270508.1 chr6 138198245 C -G c.839_839delG p.R280fs*7 NA 2.17 (55/2537) 
ID23 Training ARID1A NM_006015.4 chr1 27102199 G C c.5124+1G>C   36.88 (648/1757) 28.94 (722/2495) 
ID23 Training CD79B NM_001039933.1 chr17 62007129 C G c.552+1G>C   42.16 (390/925) 23.53 (368/1564) 
ID23 Training MYC NM_002467.4 chr8 128751037 T A c.574T>A p.Y192N 43.66 (303/694) 10.14 (73/720) 
ID23 Training MYC NM_002467.4 chr8 128751056 C T c.593C>T p.A198V 44.75 (290/648) 11.11 (86/774) 
ID23 Training MYC NM_002467.4 chr8 128750938 C G c.475C>G p.L159V 48.29 (989/2048) 18.17 (325/1789) 
ID23 Training MYC NM_002467.4 chr8 128750750 C G c.287C>G p.S96C 51.21 (1232/2406) 18.89 (221/1170) 
ID23 Training MYC NM_002467.4 chr8 128750602 T G c.139T>G p.Y47D 48.84 (609/1247) 19.38 (289/1491) 
ID23 Training MYC NM_002467.4 chr8 128750849 G A c.386G>A p.S129N - 3.66 (96/2623) 
ID23 Training MYC NM_002467.4 chr8 128750686 C T c.223C>T p.P75S 49.70 (750/1509) 8.12 (65/800) 
ID23 Training PIM1 NM_001243186.1 chr6 37139210 C G c.823C>G p.L275V - 12.45 (162/1301) 
ID23 Training PIM1 NM_001243186.1 chr6 37139114 C G c.727C>G p.L243V 84.27 (1698/2015) 39.6 (531/1341) 
ID26 Training CARD11 NM_032415.4 chr7 2984030 G A c.500C>T p.T167M NA 2.32 (29/1248) 
ID26 Training DDX3X NM_001356.3 chrX 41204667 G A c.1181G>A p.R394H NA 3.36 (14/417) 
ID26 Training FBXW7 NM_033632.3 chr4 153245397 A +T c.1793_1794insA p.N598fs*7 NA 0.75 (17/2255) 
ID26 Training LRP1B NM_018557.2 chr2 141812805 C A c.1432G>T p.D478Y NA 1.08 (15/1395) 
ID26 Training TNFAIP3 NM_001270508.1 chr6 138199911 T -G c.1330_1330delG p.E444fs*33 NA 1.14 (19/1671) 
ID26 Training ZMYM3 NM_005096.3 chrX 70464194 C A c.3238G>T p.A1080S NA 3 (26/866) 
ID28 Training ARID1A NM_006015.4 chr1 27105554 G T c.5165G>T p.R1722L 14.29 (254/1778) 17.39 (483/2777) 
ID28 Training BRAF NM_004333.4 chr7 140481403 C G c.1405G>C p.G469R - 1.69 (46/2729) 
ID28 Training CCND3 NM_001760.4 chr6 41903719 G A c.838C>T p.Q280* - 2.89 (49/1696) 
ID28 Training CCND3 NM_001760.4 chr6 41903731 G A c.826C>T p.Q276* 23.02 (399/1733) 31.31 (541/1728) 
ID28 Training IKBKB NM_001556.2 chr8 42166429 T A c.578T>A p.L193Q 18.09 (226/1249) 22.44 (438/1952) 
ID28 Training KMT2D NM_003482.3 chr12 49431113 G -C c.10025_10025delG p.R3342fs*16 12.78 (187/1463) 16.21 (406/2504) 
ID28 Training KMT2D NM_003482.3 chr12 49425455 T +G c.13032_13033insC p.K4345fs*27 30.53 (722/2365) 35.3 (1036/2935) 
ID28 Training KRAS NM_033360.2 chr12 25398281 C T c.38G>A p.G13D 29.53 (344/1165) 32.85 (837/2548)  
ID28 Training LRP1B NM_018557.2 chr2 141597656 T G c.5115-2A>C   NA 21.2 (300/1415) 
ID28 Training TBL1XR1 NM_024665.4 chr3 176767919 C T c.568G>A p.D190N 14.35 (248/1728) 18.8 (478/2543) 
ID28 Training TNFAIP3 NM_001270508.1 chr6 138199831 A T c.1249A>T p.K417* 33.05 (1084/3280) 48.55 (1437/2960) 
ID30 Training CD58 NM_001779.2 chr1 117087037 GAC G c.258_259delGT p.S87fs*2 NA 0.14 (4/2862) 
ID30 Training NOTCH1 NM_017617.3 chr9 139390846 TG T c.7344_7344delC p.P2448fs*29 NA 43.3 (294/679) 
ID30 Training PIM1 NM_001243186.1 chr6 37138805 C G c.511C>G p.L171V NA 1.91 (33/1727) 
ID30 Training STAT6 NM_003153.4 chr12 57492812 C G c.1941G>C p.K647N NA 0.57 (18/3145) 
ID30 Training TP53 NM_000546.5 chr17 7577021 CG C c.917_917delG p.R306fs*39 NA 16.93 (564/3332) 
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ID30 Training TP53 NM_000546.5 chr17 7576887 TTC T c.957_958delGA p.K320fs*16 NA 18.39 (582/3165) 
ID31 Validation CD79B NM_001039933.1 chr17 62006804 T C c.584A>G p.H195R 33.78 (586/1735) 18.65 (130/697) 
ID31 Validation MEF2B NM_001145785.1 chr19 19260064 C T c.229G>A p.E77K 39.89 (919/2304) 21.85 (248/1135) 
ID31 Validation HIST1H1E NM_005321.2 chr6 26157118 C A c.500C>A p.A167D 1.12 (25/2238) 1.49 (9/558) 
ID32 Validation TNFRSF14 NM_003820.2 chr1 2491292 C T c.335C>T p.S112F 19.17 (158/824) 75.16 (230/306) 
ID32 Validation KRAS NM_033360.2 chr12 25378562 C T c.436G>A p.A146T 28.69 (2662/9278) 55.39 (4907/8859) 
ID32 Validation MYD88 NM_001172567.1 chr3 38182025 G T c.649G>T p.V217F 15.14 (885/5846) 28.82 (1591/5521) 
ID32 Validation CD58 NM_001779.2 chr1 117087122 G A c.175C>T p.Q59* 18.47 (1987/10757) 24.90 (1953/7842) 
ID32 Validation CD58 NM_001779.2 chr1 117086941 T -AAAG c.352_355del4bp p.L118fs*11 13.92 (1003/7208) 18.60 (928/4990) 
ID32 Validation NOTCH2 NM_024408.2 chr1 120458147 G A c.7198C>T p.R2400* 15.93 (439/2756) 37.99 (827/2177) 
ID32 Validation PRDM1 NM_182907.2 chr6 106552886 G +A c.449_450insA p.R150fs*140 - 4.72 (461/9759) 
ID32 Validation CD58 NM_001779.2 chr1 117078656 A G c.559T>C p.C187R - 5.42 (403/7431) 
ID32 Validation CD58 NM_001779.2 chr1 117087208 G -A c.88_88delT p.S30fs*12 - 16.44 (1199/7291) 
ID34 Validation GNA13 NM_006572.4 chr17 63010482 A C c.1027T>G p.Y343D 31.11 (1455/4677) 1.61 (44/2740) 
ID34 Validation CREBBP NM_004380.2 chr16 3788657 A C c.4297T>G p.Y1433D 42.74 (1107/2590) 0.88 (11/1257) 
ID34 Validation KMT2D NM_003482.3 chr12 49431399 A +G c.9739_9740insC p.L3247fs*4 41.26 (861/2087) 0.62 (8/1286) 
ID34 Validation EP300 NM_001429.3 chr22 41568590 G A c.4540G>A p.E1514K - 1.56 (38/2431) 
ID35 Validation NOTCH1 NM_017617.3 chr9 139391902 G A c.6289C>T p.P2097S 1.83 (22/1203) - 
ID36 Validation EP300 NM_001429.3 chr22 41536154 A G c.1771A>G p.I591V 20.26 (1298/6406) - 
ID37 Validation TNFRSF14 NM_003820.2 chr1 2489255 T A c.160T>A p.C54S 64.57 (277/429) 10.46 (16/153) 
ID37 Validation TNFRSF14 NM_003820.2 chr1 2491399 C T c.442C>T p.Q148* 12.59 (51/405) 1.32 (2/151) 
ID37 Validation TBL1XR1 NM_024665.4 chr3 176750838 T G c.1337A>C Y446S 10.35 (300/2898) - 
ID37 Validation TBL1XR1 NM_024665.4 chr3 176750808 T A c.1367A>T p.Y456F 10.56 (300/2840) - 
ID37 Validation CARD11 NM_032415.4 chr7 2977614 T A c.1070A>T p.D357V 21.15 (246/1163) 6.33 (25/395) 
ID37 Validation CARD11 NM_032415.4 chr7 2979499 A G c.748T>C p.S250P 19.79 (977/4936) 0.71 (6/846) 
ID37 Validation EZH2 NM_004456.4 chr7 148508728 A T c.1936T>A p.Y646N 9.17 (131/1429) - 
ID37 Validation EZH2 NM_004456.4 chr7 148508727 T A c.1937A>T p.Y646F 23.47 (334/1423) 2.27 (8/353) 
ID37 Validation KMT2D NM_003482.3 chr12 49420661 G A c.15088C>T p.R5030C 35.80 (600/1676) 5.74 (50/331) 
ID37 Validation KMT2D NM_003482.3 chr12 49425836 G A c.12652C>T p.Q4218* 37.02 (810/2188) 11.18 (52/465) 
ID37 Validation BCL2 NM_000633.2 chr18 60985529 A G c.371T>C p.F124S 21.05(498/2366) 0.87 (6/687) 
ID37 Validation BCL2 NM_000633.2 chr18 60985839 A G c.61T>C p.Y21H 22.04 (410/1860) 6.35 (25/394) 
ID37 Validation BCL2 NM_000633.2 chr18 60985798 A C c.102T>G p.D34E 4.71 (74/1572) - 
ID37 Validation BCL2 NM_000633.2 chr18 60985874 T A c.26A>T P.Y9F 3.26 (63/1931) 4.77 (21/440) 
ID37 Validation CREBBP NM_004380.2 chr16 3786703 T A c.4508A>T p.Y1503F 36.15 (1624/4492) 5.71 (45/788) 
ID37 Validation CREBBP NM_004380.2 chr16 3786801 G T c.4296C>A p.H1432Q 35.80 (1142/3190) 11.42 (50/438) 
ID38 Validation HIST1H1E NM_005321.2 chr6 26156976 G A c.358G>A p.A120T 20.39 (300/1472) 10.66 (214/2007) 
ID38 Validation HIST1H1E NM_005321.2 chr6 26157154 C T c.536C>T p.A179V 25.74 (323/1255) 12.80 (182/1422) 
ID38 Validation ZMYM3 NM_005096.3 chrX 70465518 C T c.2824G>A p.D956N 63.23 (724/1145) 14.68 (143/974) 
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ID38 Validation MYC NM_002467.4 chr8 128750638 G A c.130G>A p.A44T 15.50 (93/600) 3.88 (36/929) 
ID38 Validation MYC NM_002467.4 chr8 128750677 C T c.169C>T P57S 14.54 (115/791) 4.06 (47/1159) 
ID38 Validation B2M NM_004048.2 chr15 45003780 A -CT c.37_38delCT p.L13fs*43 - 12.28 (57/464) 
ID38 Validation B2M NM_004048.2 chr15 45007851 T C c.298T>C p.C100R - 14.89 (391/2626) 
ID39 Validation CCND3 NM_001760.4 chr6 41903752 C +T c.588_589insA p.S142fs*36 35.61 (365/1025) 11.33 (176/1553) 
ID39 Validation STAT6 NM_003153.4 chr12 57496662 C T c.1255G>A p.D419N 61.8 (1016/1644) 28.09 (704/2506) 
ID41 Validation CD58 NM_001779.2 chr1 117078586 C T c.628+1G>A   - 11.07 (113/1021) 
ID41 Validation CD58 NM_001779.2 chr1 117087028 A -GG c.267_268delCC p.L90Hfs*10 - 8.86 (143/1614) 
ID41 Validation KMT2D NM_003482.3 chr12 49418670 G A c.15844C>T p.R5282* 21.96 (412/1876) 23.69 (245/1034) 
ID41 Validation KMT2D NM_003482.3 chr12 49421105 C A c.14644G>T p.E4882* 48.25 (690/1430) 40.55 (221/545) 
ID41 Validation STAT6 NM_003153.4 chr12 57496661 T C c.1256A>G p.D419G 62.82 (2491/3965) 56.29 (1253/2226) 
ID41 Validation CREBBP NM_004380.2 chr16 3900780 G A c.316C>T p.Q106* 27.33 (473/1731) 28.52 (223/782) 
ID42 Validation TNFRSF14 NM_003820.2 chr1 2489256 G T c.161G>T p.C54F 11.76(16/136) - 
ID42 Validation EZH2 NM_004456.4 chr7 148506467 G C c.2045C>G p.A682G 25.65 (198/772) 1.95 (40/2047) 
ID42 Validation CREBBP NM_004380.2 chr16 3781322 C -AAG c.5040_5042delCTT p.L1643- 20.67 (37/179) 1.34 (10/746) 
ID42 Validation BCL2 NM_000633.2 chr18 60985760 C T c.140G>A p.G47D 31.84 (149/468) - 
ID43 Validation BRAF NM_004333.4 chr7 140476786 A T c.1620T>A p.H540Q 20.37 (552/2710) 18.61 (470/2526) 
ID43 Validation KMT2D NM_003482.3 chr12 49431895 G A c.9244C>T p.R3082W 21.6 (604/2796) 16.72 (298/1782) 
ID43 Validation CD36 NM_001779.2 chr7 80303421 T A c.1377T>A p.F459L - 0.68 (20/2923) 
ID44 Validation EZH2 NM_004456.4 chr7 148508728 A T c.1936T>A p.Y646N NA 4.16 (58/1395) 
ID44 Validation KMT2D NM_003482.3 chr12 49427403 A -G c.11084_11084delC p.P3695fs*54 NA 7.2 (208/2893) 
ID44 Validation KMT2D NM_003482.3 chr12 49436416 A T c.5795T>A p.L1932* NA 4.05 (159/3926) 
ID44 Validation GNA13 NM_006572.4 chr17 63010628 T A c.596A>T p.D294V NA 4.8 (272/5667) 
ID44 Validation GNA13 NM_006572.4 chr17 63010818 T C c.691A>G  p.K231E NA 4.36 (223/5112) 
ID44 Validation EP300 NM_001429.3 chr22 41574806 T G c.7091T>G p.F2364C NA 2.07 (70/3388) 
ID46 Validation KMT2D NM_003482.3 chr12 49432396 G A c.8743C>T p.R2915* NA 8.69 (269/3096) 
ID47 Validation ITPKB NM_002221.3 chr1 226822466 C T c.2747G>A p.W916* 2.76 (66/2393) - 
ID47 Validation MYC NM_002467.4 chr8 128753192 C G c.1353C>G p.N451K 22.99 (1624/7065) - 
ID48 Validation SPEN NM_015001.2 chr1 16258541 C T c.5806C>T p.R1936* 40.23 (4199/10437) 15.39 (591/3839) 
ID48 Validation TNFAIP3 NM_001270508.1 chr6 138199805 C +A c.1223_1224insA p.E409Rfs*20 19.71 (2169/11003) 7.27 (286/3933) 
ID48 Validation EZH2 NM_004456.4 chr7 148508728 A T c.1936T>A p.Y646N 22.02 (522/2371) 5.27 (53/1004) 
ID48 Validation B2M NM_004048.2 chr15 45003773 T G c.29T>G p.L10R 17.14 (817/4767) 7.8 (38/486) 
ID48 Validation B2M NM_004048.2 chr15 45003779 T C c.35T>C p.L12P 16.54 (830/5019) 8.59 (44/512) 
ID48 Validation GNA13 NM_006572.4 chr17 63052591 C A c.121G>T p.E41* 39.83 (2297/5767) 11.81 (132/1118) 
ID49 Validation TP53 NM_000546.5 chr17 7577509 C T c.772G>A p.E258K 81.38 (647/795) 8.64 (114/1319) 
ID49 Validation GNA13 NM_006572.4 chr17 63010412 A G c.812T>C p.I366T 77.15 (1087/1409) 8.14 (310/3808) 
ID49 Validation BCL2 NM_000633.2 chr18 60985689 G A c.211C>T p.P71S 65.98 (192/291) - 
ID50 Validation TNFRSF14 NM_003820.2 chr1 2488174 T A c.69+2T>A   NA 12.33 (82/665) 
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ID50 Validation MYD88 NM_001172567.1 chr3 38182032 C G c.656C>G p.S219C NA 13.03 (265/2034) 
ID50 Validation KLHL6 NM_130446.2 chr3 183209942 C T c.1639G>A p.E547K NA 12.41 (259/2087) 
ID50 Validation FBXW7 NM_033632.3 chr4 153247247 A C c.1027T>G p.Y519D NA 15.12 (608/4020) 
ID51 Validation SPEN NM_015001.2 chr1 16203031 T A c.739T>A p.S247T - 1.44 (27/1879) 
ID51 Validation SPEN NM_015001.2 chr1 16261464 A T c.8729A>T p.E2910V - 1.22 (29/2381) 
ID51 Validation MYD88 NM_001172567.1 chr3 38182641 T C c.818T>C p.L265P 20.91 (413/1975) 8.86 (114/1286) 
ID51 Validation HIST1H1E NM_005321.2 chr6 26157144 G A c.526G>A p.A176T - 1.58 (31/1965) 
ID51 Validation PIM1 NM_001243186.1 chr6 37139063 G A c.403G>A p.E135K 21.72 (425/1957) 9.81 (116/1183) 
ID51 Validation PIM1 NM_001243186.1 chr6 37138549 G A c.356G>A p.G119D 16.87 (122/723) - 
ID51 Validation CD79B NM_001039933.1 chr17 62006647 A C c.632T>G p.I211R 24.05 (416/1730) 4.06 (50/1232) 
ID51 Validation CD79B NM_001039933.1 chr17 62006674 A G c.605T>C p.I202T 22.69 (435/1917) 4.76 (69/1451) 
ID51 Validation CD79B NM_001039933.1 chr17 62006799 A C c.589T>G p.Y197D 24.05 (404/1680) 7.49 (78/1042) 
ID52 Validation ARID1A NM_006015.4 chr1 27101054 C T c.4336C>T p.R1446* 12.13 (151/1245) 9.85 (91/924) 
ID52 Validation ITPKB NM_002221.3 chr1 226924223 T C c.936_936delC p.T313fs*86 12 (303/2524) 4.87 (75/1539) 
ID52 Validation TNFAIP3 NM_001270508.1 chr6 138196027 G A c.341G>A p.G114D 24.35 (809/3322) 16.67 (231/1386) 
ID52 Validation HIST1H1E NM_005321.2 chr6 26156852 C A c.234C>A p.S78R - 2.35 (34/1449) 
ID52 Validation TNFAIP3 NM_001270508.1 chr6 138200387 C -G c.1806_1806delG p.T604fs*93 25.18 (1634/6489) 16.55 (455/2749) 
ID52 Validation STAT6 NM_003153.4 chr12 57496654 A T c.1263T>A p.N421K 24.34 (572/2350) 11.61 (119/1025) 
ID52 Validation TP53 NM_000546.5 chr17 7578406 C T c.524G>A p.R175H 28.71 (552/1923) 11.17 (86/770) 
ID53 Validation PRDM1 NM_182907.2 chr6 106553111 C T c.968C>T p.T359M NA 1.54 (42/2736) 
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FIGURES LEGENDS 
Figure 1. Prevalence and molecular spectrum of non-synonymous somatic mutations discovered in 
plasma cfDNA. Percentage of training (A) and validation (D) DLBCL cases harboring non-synonymous 
somatic mutations of genes investigated by targeted-resequencing of plasma cfDNA. Color codes 
indicate the distribution of mutations among germinal center (GC) and non-GC DLBCL. The final 
number and prevalence of mutated cases is given for each gene. Molecular spectrum of non-
synonymous somatic mutations identified in plasma cfDNA of the training (B) and validation (E) DLBCL 
cases compared to the molecular spectrum of non-synonymous somatic mutations that have been 
detected in tumor gDNA of published DLBCL series and reported in the COSMIC database (v76). Genes 
mutated in >10% cases of the DLBCL series are reported. Position and type of non-synonymous somatic 
mutations identified in plasma cfDNA of the training (C) and validation (F) DLBCL cases. Genes mutated 
in >10% cases are reported. Mutation maps were obtained through MutationMapper v1.0.1.  
 
Figure 2. Overview of the DLBCL genotype discovered in tumor gDNA. Case-level mutational profiles 
of 20 training (A) and 16 validation (B) DLBCL tumors genotyped on gDNA from the tissue biopsy. Each 
column represents one tumor sample, each row represents one gene. The fraction of tumors with 
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mutations in each gene is plotted on the right. The number of mutations in a given tumor is plotted 
above the heat map. Cases are clustered according to the cell of origin. 
 
Figure 3. Concordance between plasma cfDNA and tumor gDNA genotyping. Number of mutations in 
a given tumor discovered in plasma cfDNA and/or tumor gDNA in the training (A) and validation (D) 
DLBCL (cases provided of paired plasma cfDNA and tumor biopsy gDNA are represented). Mutations 
are color coded if they were identified in both plasma cfDNA and tumor biopsy gDNA (red), only in 
plasma cfDNA (blue), or only in tumor biopsy gDNA (grey). Venn diagram summarizing the overall 
number of mutations discovered in both plasma cfDNA and tumor biopsy gDNA (red), only in plasma 
cfDNA (blue), or only in tumor biopsy gDNA (grey) from the training (B) and validation (E) DLBCL. The 
corresponding overall sensitivity of plasma cfDNA genotyping in discovering biopsy-confirmed 
mutations is shown. Fraction of tumor biopsy-confirmed mutations that were detected in plasma 
cfDNA in the training (C) and validation (F) DLBCL. Patients are ordered by decreasing detection rates. 
The training cohort included two patients (ID2 and ID14) who were not informative because devoid of 
mutations within the target region. The black portion of the bars marks the prevalence of tumor 
biopsy-confirmed mutations that were detected in plasma cfDNA. The gray portion of the bars marks 
the prevalence of tumor biopsy-confirmed mutations that were not detected in plasma cfDNA.  
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Figure 4. Accuracy of plasma cfDNA genotyping vs tumor gDNA genotyping. The mutation abundance 
in plasma cfDNA vs the mutation abundance in tumor gDNA is comparatively represented in the 
scatterplot for each variant identified in the training (A) and validation (C) DLBCL cases. Receiver 
operating characteristic (ROC) illustrating the performance of plasma cfDNA genotyping in detecting 
biopsy confirmed tumor variants according to the variant allele frequency of mutations in tumor gDNA 
in the training (B) and validation (D) DLBCL cases. The bar graph shows the allele frequency in tumor 
gDNA of the variants that were discovered in plasma cfDNA (red bars) or missed in plasma cfDNA (grey 
bars). The dash line tracks the 20% variant allele frequency threshold.  
 
Figure 5. Detection of a FBXW7 mutation in genomic tumor DNA from DLBCL cells of the 
cerebrospinal fluid. The p.S688G FBXW7 somatic mutation was detected in the tumor gDNA from 
DLBCL cells of the cerebrospinal fluid at 0.42% frequency above the background, passing the 
identification cut-offs established by Bonferroni-corrected probabilities.  
 
Figure 6. Longitudinal assessment of mutation abundance in plasma cfDNA upon R-CHOP treatment. 
The graphs represent the variant allele frequency of non-synonymous somatic mutations in plasma 
cfDNA at baseline before treatment start, before each R-CHOP course, and at the end of treatment. 
Responding (A) and non-responding (B) patients are pooled in the graphs. Each dot represents one 
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single individual mutation. Among responding patients (A), baseline mutations (n=102; mean allele 
frequency 12.6%, range 0.17%-80.4%) disappeared from plasma cfDNA. Among non-responding 
patients (B), baseline mutations (n=27; mean allele frequency 14.3%, range 0.14-53.9%) remain 
detectable in plasma cfDNA before R-CHOP cycle 2 (mean allele frequency 20.2%, range 0.65%-65.3%), 
before R-CHOP cycle 3 (mean allele frequency 18.8%, range 1.1-61.1%), and at the end of treatment 
(mean allele frequency 8.2%, range 0.1-34.2%). 
 
Figure 7. Non-invasive real-time monitoring of the DLBCL clonal evolution on plasma cfDNA. 
Sequential analysis of plasma cfDNA collected at presentation, upon treatment and at the end of 
treatment. Disease response assessment by CT/PET is also shown at the corresponding timepoints. 
Representative patients are shown. Among non-responding patients (ID13 and ID12), baseline 
mutations remain detectable in plasma cfDNA. Among relapsing patients, baseline mutations cleared 
from plasma cfDNA and appeared again at the time of relapse (ID1) or persisted despite clinical 
remission (ID9). Color codes indicate different variants. Gene mutations selected by treatment are 
highlighted.
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Figure 1. Prevalence and molecular spectrum of non-synonymous somatic mutations discovered in plasma cfDNA. 
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Figure 2. Overview of the DLBCL genotype discovered in tumor gDNA. 
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Figure 3. Concordance between plasma cfDNA and tumor gDNA genotyping.
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Figure 4. Accuracy of plasma cfDNA genotyping vs tumor gDNA genotyping. 
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Figure 5. Detection of a FBXW7 mutation in genomic tumor DNA from DLBCL cells of the 
cerebrospinal fluid. 
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Figure 6. Longitudinal assessment of mutation abundance in plasma cfDNA upon R-CHOP treatment. 
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Figure 7. Non-invasive real-time monitoring of the DLBCL clonal evolution on plasma cfDNA. 
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 SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. Experimental validation of plasma cfDNA mutations identified by CAPP-seq. The 
x axis shows the variant allele frequency of the non-synonymous somatic mutations by the discovery CAPP-
seq experiment. The y axis shows the variant allele frequency of the non-synonymous somatic mutations by 
the validation CAPP-seq experiment. Each dot represents one single individual mutation. The coefficient of 
correlation (R2) between the two experiments is shown. Panel A shows the biopsy confirmed variants. Panel 
B shows the variants discovered in plasma cfDNA but not in tumor gDNA.  
 
Supplementary Figure 2. Sanger sequencing validation of mutations discovered in plasma cfDNA. Sanger 
sequencing was used to validate the most abundant plasma cfDNA mutations detected by CAPP-seq. 
Exemplificative results are shown. The electropherograms show plasma cfDNA mutations that have a variant 
allele frequency >8%. 
 
Supplementary Figure 3. Analysis of plasma cfDNA from healthy donors by CAPP-seq. (A) The three peaks 
represent kernel distribution density plots of the frequencies of allele fractions in plasma cfDNA from DLBCL 
patients. By their low concentrations, somatic mutations (far left-hand small peak) can be generally 
distinguished from heterozygous (middle peak) and homozygous (right-hand peak) germline SNV listed in the 
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dbSNP138. The bottom dot plot represents the allele frequency of variants (in red somatic mutations, in grey 
germline SNV) (B) The two peaks represent kernel distribution density plots of the allele fractions in healthy 
donors. Heterozygous (middle peak) and homozygous (right-hand peak) germline SNV listed in the dbSNP138 
are shown. Conversely, no far left-hand small peaks are visible indicating that the CAPP-seq approach does 
not pick up biological or analytical background noise in cfDNA. Plots are derived by deflagging dbSNP138 
polymorphisms from filters applied to the final list of variants called by the algorithm. The bottom dot plot 
represents the allele frequency of variants (in grey germline SNV). 
 
Supplementary Figure 4. Pairwise CAPP-seq of samples provided with both fresh and FFPE tissue biopsies. 
The graph comparatively shows the allele frequency of mutations in gDNA from paired fresh/FFPE samples 
processed from the same DLBCL biopsy. 
 
Supplementary Figure 5. Coverage across the target region. Depth of coverage (y axis) across the target 
region (x axis) by CAPP-seq of plasma cfDNA from the training DLBCL (n=30) (A), of tumor gDNA from fresh 
biopsies of the training DLBCL (n=17) (B), of tumor gDNA from FFPE biopsies of the training DLBCL (n=3) (C), 
of plasma cfDNA from the validation DLBCL (n=20) (D), of tumor gDNA from fresh biopsies of the validation 
DLBCL (n=8) (E), of tumor gDNA from FFPE biopsies of the validation DLBCL (n=8) (F). Each dot represents the 
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sequencing depth on that specific position of the target region of one single individual sample. The solid blue 
line shows the median depth of coverage, while the dash blue lines show the interquartile range. 
 
Supplementary Figure 6. Correlation between tumor cfDNA load in plasma and clinical indices. Panel A 
shows disease stage. Panel B shows LDH levels. The band inside the box is the median tumor cfDNA load in 
plasma across patients, the bottom and top of the box are the first and third quartiles, and the ends of the 
whiskers represent the range. For each patient, the variant showing the larges allele frequency in plasma was 
considered as the marker of the tumor cfDNA load in plasma.   
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Supplementary Figure 1. Experimental validation of plasma cfDNA mutations identified by CAPP-seq. 
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Supplementary Figure 2. Sanger sequencing validation of mutations discovered in plasma cfDNA. 
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Supplementary Figure 3. Analysis of plasma cfDNA from healthy donors by CAPP-seq. 
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Supplementary Figure 4. Pairwise CAPP-seq of samples provided with both fresh and FFPE tissue biopsies. 
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Supplementary Figure 5. Coverage across the target region. 
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Supplementary Figure 6. Correlation between tumor cfDNA load in plasma and clinical indices. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 
 
 
RINGRAZIAMENTI 
 
Dopo tre lunghi e intensi anni, finalmente termino il dottorato di ricerca. È stato un periodo di profondo 
apprendimento, non solo a livello scientifico, ma anche personale. Vorrei spendere due parole di 
ringraziamento nei confronti di tutte le persone che mi hanno sostenuto, sopportato e aiutato durante 
questo periodo. 
  Al Professor Gianluca Gaidano, Direttore del Laboratorio di Ematologia presso il Dipartimento 
di Medicina Traslazionale dell’Università del Piemonte Orientale, relatore di questa tesi di laurea e mio 
mentore, per l’aiuto, il sostegno e la disponibilità fornitomi in tutti questi anni e la grande conoscenza 
che mi ha donato.  
  A tutti i miei colleghi/amici: Chiara Favini, Simone Favini, Denise Peroni, Silvia Rasi, Sruthi 
Sagiraju, Riccardo Moia e Clara Deambrogi.  Ci siamo sempre sostenuti a vicenda, nella buona e nella 
cattiva sorte, sia durante le fatiche e lo sconforto che hanno caratterizzato il mio percorso, sia nei 
momenti di gioia e soddisfazione. Quindi grazie di esserci stati fino all’ultimo. Avete avuto un peso 
determinante nel conseguimento di questo risultato, grazie infinite per la pazienza, la disponibilità, 
l’aiuto e tutti i preziosi consigli che mi avete elargito. Grazie per avermi aiutato a sopravvivere a questi 
tre anni. Vi voglio bene. 
79 
 
  A tutti i collaboratori del laboratorio di Ematologia, Ramesh Adhinaveni, Ahad Kodipad, 
Davide Rossi, Alessio Bruscaggin, Valeria Spina, tutti i medici del reparto di ematologia dell’Ospedale 
maggiore della carità di Novara. 
  Alla mia famiglia per il sostegno durante questi anni. Un grazie particolare a mia madre per 
non aver mai smesso di credere in me e per non avermi permesso di smettere di credere in me stessa. 
  A tutti gli amministrativi e agli informatici, in particolare, Ingrid Cappa, Maurizio Pietroni, 
Ferdinando Maffia, Anna Rapa, Letizia Iadanza e Roberto Serra. 
  All’agenzia viaggi Novarseti, in particolare a Giusi Ferraris per tutto l’aiuto e la pazienza. 
  All’Associazione Italiana contro le Leucemie, Linfomi e Mieloma (A.I.L.) per l’aiuto e il 
sostegno che mi ha dato nella mia crescita professionale. 
  Per ultimi ma non meno importanti, i miei amici (tutti quanti!!). Grazie per la vostra costante 
ma discreta presenza. 
 
 
 
 
